RIGEL PHARMACEUTICALS INC 8-K

What Happened
Rigel Pharmaceuticals, Inc. announced its financial results for the quarter ended March 31, 2026, and furnished a press release titled “Rigel Reports First Quarter 2026 Financial Results” as Exhibit 99.1 to an 8-K filed May 5, 2026. The filing was signed by Raymond J. Furey, Executive Vice President, General Counsel and Corporate Secretary. The 8-K was filed under Item 2.02 (Results of Operations and Financial Condition).

Key Details

• Filing date: May 5, 2026; quarter covered: Q1 ended March 31, 2026.
• Item reported: 2.02 — Results of Operations and Financial Condition (press release furnished).
• Exhibit included: 99.1 — press release “Rigel Reports First Quarter 2026 Financial Results” (and Exhibit 104: Inline XBRL cover page).
• Signed by: Raymond J. Furey, EVP, General Counsel, Chief Compliance Officer, and Corporate Secretary.

Why It Matters
This 8-K notifies investors that Rigel has released its quarterly results (earnings and revenue) for Q1 2026; investors should review the furnished press release for the specific revenue, earnings, and any commentary on business performance or guidance. Timely disclosure of quarterly results can affect the company’s stock price and informs decisions by shareholders and analysts; this filing furnishes the press release rather than presenting amended financial statements.